Nuwellis Seeks FDA Pediatric Expansion for Aquadex

The medtech company asks the agency to extend its Aquadex SmartFlow System to children weighing 5 kilograms and above.

Updated on Nov. 5, 2026 in Children’s Health

Clear medical tubing coiled on a stainless steel tray beside a sealed fluid bag in a bright, empty clinical room. — Nuwellis asked the U.S. Food and Drug Administration to expand its Aquadex SmartFlow System to children weighing 5 kilograms and above. AI Illustration. Upload story photo >

Nuwellis submitted a 510(k) premarket notification to the U.S. Food and Drug Administration to expand the Aquadex SmartFlow System's indication to pediatric patients weighing 5 kg and above. The Aquadex SmartFlow System is currently cleared for patients weighing 20 kg and above.

Why it matters

The expansion would broaden labeled use of the device to smaller children who are currently outside its cleared population. Nuwellis says the submission is built on peer-reviewed pediatric clinical evidence, including the ULTRA-Peds Registry.

The supporting evidence is a multicenter registry of 91 pediatric patients, 67 of whom weighed under 20 kg, compared against the device's current 20 kg minimum. The FDA's decision on the expanded indication has not been made.

The players

Nuwellis

A Nasdaq-listed medical technology company headquartered in Minneapolis that makes the Aquadex SmartFlow System for fluid removal.

U.S. Food and Drug Administration

The federal agency responsible for reviewing and clearing medical devices, including premarket notifications submitted under the 510(k) pathway.

The details

The 510(k) submission follows a pre-submission meeting with the FDA held in April 2026 and includes existing performance verification data, pediatric-specific safety analyses, and updated toxicological assessments. Nuwellis also announced that the ULTRA-Peds Registry was accepted for publication in Pediatric Nephrology.

April 2026: Nuwellis held a pre-submission meeting with the FDA.
October 27, 2026: Nuwellis announced acceptance of the ULTRA-Peds Registry for publication.
November 5, 2026: Nuwellis announced the 510(k) submission to the FDA.

Roadmap

The filing extends a device already cleared under the FDA's 510(k) pathway into younger pediatric patients rather than creating a new category. It reflects a broader push by device makers to expand labeled pediatric use with registry evidence.

If cleared, the expanded labeling could make the Aquadex treatment an option for children weighing as little as 5 kg, rather than only those at 20 kg and above. Families and clinicians would still need to weigh the device's temporary-use profile, which is limited to 8 hours.

The takeaway

Expanding a device's labeled population depends on pediatric-specific evidence, so smaller patients are typically added only after registry data supports their safety. The outcome of the FDA review will determine whether that evidence translates into broader clinical access.